Segmentation by type classifies the Cell Activity Assay Service market into four methodological families: luminescence‑based, fluorescence‑based, label‑free, and impedance assays. Luminescence‑based assays dominate due to their high sensitivity and broad dynamic range, supporting enzymatic and ATP‑measurement workflows that attract mid‑to‑high‑value contracts. Fluorescence‑based assays, encompassing FRET, FLIM, and high‑content imaging, provide multiplexing capability, appealing to projects requiring phenotypic profiling; they represent a significant, though slightly smaller, revenue slice. Label‑free technologies, such as surface plasmon resonance and mass‑sensitive detection, address mechanistic studies where perturbation‑free readouts are essential, contributing a niche but growing share as instrument costs decline. Impedance assays capture real‑time cellular electrophysiology, supporting cardiotoxicity and barrier integrity studies, and occupy a specialized segment with premium pricing. Each type’s analytical strengths and instrument investment requirements dictate its proportional contribution to the overall market, reinforcing the nuanced market taxonomy within Cell Activity Assay Services.